巴尔通体对19种抗生素体外敏感性分析

目的 检测巴尔通体菌株对10类19种抗生素最低抑菌浓度（MICs）,分析药物敏感性及耐药性,为指导临床用药和耐药监测提供实验和数据参考。方法 采用E试验法,检测巴尔通体属11种、35株菌株对强力霉素、阿奇霉素、利福平等19种抗生素的MICs。将培养的巴尔通体菌制成McFarland（MCF）2.0浊度的菌悬液,均匀涂布于含5%去纤维羊血的胰酶大豆琼脂培养基上,置5% CO2的37℃培养箱培养。培养5~7 d后判读MICs。结果 35株巴尔通体菌在体外对强力霉素、阿奇霉素、红霉素、克拉仙霉素等13种抗生素敏感,MICs 0.016 mg/L;34株对利福平敏感,MICs 0.002 mg/L;对克林霉素、丁胺卡那霉素、万古霉素、多粘菌素和磺胺类5种抗生素不敏感,MICs较高。结论 绝大多数巴尔通体菌对强力霉素等14种抗生素敏感,但也对克林霉素等5种抗生素不敏感,在对巴尔通体病进行治疗时要注意选择敏感药物。     

新疆哈巴河县2008-2013年包虫病防治项目实施效果评价

目的分析新疆哈巴河县包虫病防治项目实施效果,为包虫病的防治提供依据。方法收集2008-2013年全县人群筛查、犬感染情况、儿童感染情况和中间宿主羊患病情况等监测数据进行分析。结果全县共筛查42 356人次,查出患者161人,推算目前全县包虫病患病率为0.38%。共检测4~6岁儿童血清样本7 195人份,其中阳性样本337人份,儿童血清棘球蚴抗体阳性率由2010年的6.50%下降至2013年的2.20%,呈逐年下降趋势(χ2趋势=32.30,P<0.001)。共检测犬粪样本5 300份,其中阳性样本160份,犬粪抗原阳性率由2008年的11.60%下降至2013年的1.58%,呈逐年下降趋势(χ2趋势=58.88,P<0.001)。共检查0~2岁羊3 830只,其中患病281只,中间宿主羊的患病率由2008年的27.20%下降至2013年的2.40%,呈逐年下降趋势(χ2趋势=298.9,P<0.001)。结论包虫病防治项目实施6年来,基本摸清了哈巴河县包虫病流行底数,在降低当地终末宿主犬的棘球绦虫感染率,儿童血清棘球蚴抗体阳性率和中间宿主羊的患病率方面效果显著,应该长期坚持。     

Peripherally inserted central catheter-related bloodstream infections in patients with hematological malignancies: A retrospective 7-years single-center study

ObjectivesWe sought to investigate the nature and incidence of bloodstream infection complications and to identify the risk factors of central catheter-related bloodstream infections (CRBSI).MethodsDuring the study period, 291 consecutive patients with hematological malignancies who underwent PICC placement were retrospectively enrolled. We analyzed the covariates that were specified a priori for their association with CRBSI through multivariate Cox proportional hazards regression models. The association between each predictor and the related outcome was expressed using hazard ratios (HRs) with corresponding 95% confidence intervals (CIs).ResultsOf 391 peripherally inserted central catheter (PICCs) were inserted in 291 patients for a total of 63,714 catheter days during 7 years, with an infection rate of 0.71/1,000 catheter days. Among the patients with hematological malignancies, those with acute leukemia were prone to CRBSI. Having previous bloodstream infection (BSI) (HR 18.139; 95% CI, 8.19-40.174; P < .0001), the number of PICCs insertions (HR 4.695; 95% CI, 1.842-11.967; P = .001) (twice), (HR 6.794; 95% CI, 1.909-24.181; P = .003) (≥3 times) were significantly associated with CRBSI. Not accompanied by chronic comorbidities (HR 0.34; 95% CI, 0.131-0.887; P = .028) and longer duration of PICC use (days) (HR 0.997; 95% CI, 0.994-0.999; P = .008) might be protective factors preventing CRBSI.ConclusionsOur finding suggests that previous BSI and a higher number of PICC insertions are associated with an increased risk of CRBSI. A lack of chronic comorbidities may help prevent CRBSI.     

Vaxvec: The first web-based recombinant vaccine vector database and its data analysis

A recombinant vector vaccine uses an attenuated virus, bacterium, or parasite as the carrier to express a heterologous antigen(s). Many recombinant vaccine vectors and related vaccines have been developed and extensively investigated. To compare and better understand recombinant vectors and vaccines, we have generated Vaxvec (http://www.violinet.org/vaxvec), the first web-based database that stores various recombinant vaccine vectors and those experimentally verified vaccines that use these vectors. Vaxvec has now included 59 vaccine vectors that have been used in 196 recombinant vector vaccines against 66 pathogens and cancers. These vectors are classified to 41 viral vectors, 15 bacterial vectors, 1 parasitic vector, and 1 fungal vector. The most commonly used viral vaccine vectors are double-stranded DNA viruses, including herpesviruses, adenoviruses, and poxviruses. For example, Vaxvec includes 63 poxvirus-based recombinant vaccines for over 20 pathogens and cancers. Vaxvec collects 30 recombinant vector influenza vaccines that use 17 recombinant vectors and were experimentally tested in 7 animal models. In addition, over 60 protective antigens used in recombinant vector vaccines are annotated and analyzed. User-friendly web-interfaces are available for querying various data in Vaxvec. To support data exchange, the information of vaccine vectors, vaccines, and related information is stored in the Vaccine Ontology (VO). Vaxvec is a timely and vital source of vaccine vector database and facilitates efficient vaccine vector research and development.     

The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial

BackgroundNew, more effective vaccines to prevent tuberculosis (TB) disease are needed urgently. H4:IC31 is an investigational vaccine that contains a fusion protein of the immunodominant antigens TB10.4 and Ag85B, formulated in IC31^® adjuvant. We assessed the safety and immunogenicity of H4:IC31 in South African adults from a TB endemic setting.MethodsIn this double blind, placebo controlled, phase I trial, Mycobacterium tuberculosis-uninfected, HIV-uninfected, healthy adults with a history of childhood BCG vaccination were randomly allocated to two intramuscular vaccinations with 5, 15, 50 or 150 μg H4 formulated in 500 nmol IC31^®, two months apart. Vaccinees were followed for six months to assess safety; immunogenicity was measured by ELISpot and intracellular cytokine staining assays.ResultsThirty-two participants received H4:IC31 and 8 received placebo. Injection site adverse events were common but mild; mild fatigue was the most common systemic adverse event. Frequencies of adverse events did not differ between dosage groups. Detectable antigen-specific CD4 T cell responses were induced by all doses of H4:IC31, but doses below 50 μg induced the highest frequencies of CD4 T cells, comprised predominantly of IFN-γ⁺TNF-α⁺IL-2⁺ or TNF-α⁺IL-2⁺ cells. These memory responses persisted up to the end of follow up, on study day 182.ConclusionsH4:IC31 demonstrated an acceptable safety profile and was immunogenic in South African adults. In this trial, the 15 μg dose appeared to induce the most optimal immune response.     

Prospective effects of pedometer use and class competitions on physical activity in youth: A cluster-randomized controlled trial

ObjectiveTo evaluate the immediate effects of a school-based multi-component program to foster a physically active lifestyle in adolescence.Design/participantsIn a cluster-randomized controlled trial with pre- and post-assessment in 2014, 29 schools with 1162 8th grade students (48% girls) from Germany were included. Age ranged from 12 to 17 years (M = 13.74; SD = 0.67).InterventionWhile the control group attended education as usual, students in the intervention group received pedometers and took part in a class competition over a time period of 12 weeks. Classes with the most steps and best creative ideas to promote physical activity in everyday life were awarded.Main outcome measuresPrimary outcomes included out-of-school sports activities (h/week), moderate to vigorous physical activity (days/week with a minimum of 60 min), active commuting (min/day), doing chores (min/day), and sedentary behavior (h/day) assessed through self-administered questionnaires as well as cardiorespiratory fitness measured using the 20-m shuttle-run test (completed laps).ResultsSignificant interaction terms between group and wave of assessment were found on out-of-school sports activities (b = − 1.09 [− 1.89; − 0.29], p = 0.008), moderate to vigorous physical activity (b = − 0.29 [− 0.47; − 0.10], p = 0.002), and active commuting (b = − 20.41 [− 32.32; − 8.49], p = 0.001): students in the intervention group showed a higher increase of physical activity levels than students in the control group. The intervention effect on cardiorespiratory fitness missed significance marginally (b = − 1.52 [− 3.14; 0.98], p = 0.065), There was no effect on students' sedentary behavior (b = 0.06 [− 0.72; 0.84], p = 0.881).ConclusionsAn easy to administer school-based physical activity program (12 weeks) may enhance students' leisure-time physical activity.Trial registration number: ISRCTN49482118     

热带假丝酵母菌临床分离株毒力表型特征研究

目的 描述临床分离的热带假丝酵母菌培养不同时间的天冬氨酰蛋白酶活性(蛋白酶活性)、磷脂酶活性和溶血活性,并分析不同感染部位分离菌的蛋白酶活性和溶血活性差异。方法 将分离自不同感染部位的热带假丝酵母菌鉴定后分别接种在牛血清蛋白培养基、卵黄琼脂培养基和羊血琼脂培养基上,培养不同时间(24、48和72 h)后检测蛋白酶活性、磷脂酶活性和溶血活性。结果 热带假丝酵母菌培养24、48和72 h时均具有蛋白酶活性和溶血活性,但未表现出磷脂酶活性;热带假丝酵母菌在48 和72 h时的蛋白酶活性高于其在24 h时的活性,在72 h范围内,溶血活性随培养时间延长持续增长;分离自不同感染部位的热带假丝酵母菌的蛋白酶活性(P=0.368)和溶血活性(P=0.985)差异无统计学意义。结论 我国热带假丝酵母菌临床分离株培养不同时间具有蛋白酶活性和溶血活性,但无磷脂酶活性。     

中国10省(市)流感成年人住院病例的临床特征及重症危险因素分析

目的 了解中国10省(市)严重急性呼吸道感染(SARI)住院病例哨点监测纳入的流感成年人住院病例的临床特征及重症危险因素。方法 对2009年12月至2014年6月中国10省(市)SARI哨点监测医院纳入的符合SARI定义的≥15岁病例进行流行病学和临床信息调查,采集呼吸道标本进行流感病毒核酸检测。按检测结果将病例分为流感住院组和非流感住院组,分析两组人口统计学信息、临床和流行病学特征,并分析重症危险因素。结果 10家哨点医院共纳入3 071例SARI成年人病例,其中实验室确诊240例(7.8%),以A(H1N1)pdm2009和A(H3N2)亚型流感病毒为主。病例年龄M为63岁,≥65岁老年人占47.1%。144例(60.0%)患有至少1种慢性基础性疾病,流感病例肺气肿比例(7.9%)高于非流感病例(3.8%),差异有统计学意义(χ²=3.963,P=0.047)。19.4%的流感育龄妇女为孕妇,240例流感病例中仅有1.1%在过去一年接种过流感疫苗。流感住院病例中咽痛、呼吸困难所占比例高于非流感住院病例。17.5%的流感病例收入重症监护室治疗,与非流感住院病例间的差异无统计学意义(P=0.160)。23.1%的流感病例在发病后使用了抗病毒药物治疗,高于非流感住院组(4.8%),差异有统计学意义(P<0.001)。流感住院病例中41.5%出现并发症,病毒性肺炎比例明显高于非流感组(P<0.001)。危险因素分析显示,发病入院时间>7 d(RR=1.673,95%CI:1.071～2.614)、患有哮喘(RR=15.200,95%CI:1.157～199.633)、免疫抑制疾病(RR=5.250,95%CI:1.255～21.960)、怀孕(RR=21.000,95%CI:1.734～254.275)是流感重症的危险因素。结论 成年人流感住院病例主要集中在≥65岁组,流感疫苗接种率极低、抗病毒药物使用不足,应推荐孕妇、老年人、慢性病病例等高危人群每年进行流感疫苗预防接种,流感住院病例应及早应用抗病毒药物。     

The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence

Therapeutic vaccines for nicotine addiction show pre-clinical efficacy. Yet, clinical evaluation of the first-generation nicotine vaccines did not meet expectations because only a subset of immunized subjects achieved effective serum antibody levels. Recent studies suggest that vaccine design affects B cell activation, and that the frequency of the hapten-specific B cell subsets contributes to vaccine efficacy against drugs of abuse. To extend this hypothesis to nicotine immunogens, we synthesized a novel hapten containing a carboxymethylureido group at the 2-position of the nicotine structure (2CMUNic) and compared its efficacy to the previously characterized 6CMUNic hapten. Haptens were conjugated to the keyhole limpet hemocyanin (KLH) carrier protein, and evaluated for efficacy against nicotine in mice using the clinically approved alum adjuvant. Using a novel fluorescent antigen-based magnetic enrichment strategy paired with multicolor flow cytometry analysis, polyclonal hapten-specific B cell subsets were measured in mice immunized with either 6CMUNic-KLH or 2CMUNic-KLH. The 6CMUNic-KLH showed significantly greater efficacy than 2CMUNic-KLH on nicotine distribution to serum and to the brain. The 6CMUNic-KLH elicited higher anti-nicotine serum antibody titers, and greater expansion of hapten-specific B cells than 2CMUNic-KLH. Within the splenic polyclonal B cell population, a higher number of hapten-specific IgM^high and germinal centre B cells predicted greater vaccine efficacy against nicotine distribution. These early pre-clinical findings suggest that hapten structure affects activation of B cells, and that variations in the frequency of early-activated hapten-specific B cell subsets underlie individual differences in vaccine efficacy.